Clinical Perspective
The orforglipron Phase 3 program demonstrates a credible advance in oral GLP-1 therapy. While efficacy remains modestly below top-performing injectables, it substantially improves accessibility and adherence potential. The FDA approved orforglipron as Foundayo for chronic weight management on April 1, 2026.
Summary
Overview
Eli Lilly designed parallel late-stage trials to answer two critical questions:
Can an oral, non-fasting GLP-1 achieve clinically meaningful weight loss in obesity?
Can orforglipron outperform the current oral standard (semaglutide) in type 2 diabetes?
Development History
Orforglipron's path from early safety studies to pivotal Phase 3 trials
Obesity Trial
- 11.2% weight loss (36 mg) vs 2.0% placebo over 72 weeks
- 36% achieved ≥15% weight loss
- 73% achieved ≥5% weight loss
- N=3,127 participants
Pivotal trial demonstrating oral GLP-1 efficacy without fasting requirements. Results position orforglipron between oral semaglutide (6-8% loss) and injectables (15-21% loss)—providing a middle-ground option.
Part of the multi-trial Phase 3 program that supported the FDA application. Approved as Foundayo, it offers an alternative for patients who cannot or prefer not to use injections.
- BMI ≥ 30 kg/m² or ≥ 27 kg/m² with comorbidity
- Ages 18-75 years
- No type 2 diabetes diagnosis
- Stable weight (±5%) for 3 months prior to screening
- Type 2 diabetes
- Prior GLP-1 receptor agonist use
- Recent bariatric surgery
ATTAIN-1 evaluated three active doses against placebo, revealing a clear dose-dependent effect:[1]
Study Arms
- Orforglipron 36 mg daily → −11.2% weight loss
- Orforglipron 12 mg daily → −8.4% weight loss
- Orforglipron 6 mg daily → −7.5% weight loss
- Placebo → −2.1% weight loss
Dose Escalation Protocol: All participants started at 3 mg, with increases every 4 weeks until reaching target dose by Week 16 to minimize GI side effects.
The 36 mg dose demonstrated optimal balance between efficacy and tolerability, and is expected to be the approved dose if FDA approves the application.
- ≥20% weight loss: 12% of participants on 36 mg dose
- Weight loss trajectory: Losses progressed steadily through Week 72 without plateau, suggesting durability beyond early GLP-1–mediated appetite suppression and potential for continued benefit if treatment extended.[1]
Analysis of treatment effects across patient subgroups demonstrated consistent efficacy regardless of baseline characteristics:[1]
- By Sex: Orforglipron was effective in both male and female participants, with no significant differences in weight loss between sexes.
- By Age: Weight loss was consistent across all age groups (18-75 years), indicating that age did not significantly affect treatment response.
- By Baseline BMI: Efficacy was maintained across BMI categories, though participants with higher baseline BMI showed slightly greater absolute weight loss in kilograms.
- By Race/Ethnicity: Treatment effects were consistent across racial and ethnic groups, with no treatment-by-subgroup interactions observed.
Clinical Implication: The broad efficacy across demographic subgroups suggests orforglipron can be effective for a diverse range of patients with obesity.
| Characteristic | Orforglipron 36 mg | Placebo |
|---|---|---|
| N | 190 | 190 |
| Mean Age | 47.2 yrs | 46.8 yrs |
| Female | 72% | 70% |
| Mean BMI | 37.4 kg/m² | 37.2 kg/m² |
| Mean Weight | 105.6 kg | 104.8 kg |
| Prediabetes | 45% | 44% |
| Hypertension | 52% | 50% |
A representative, predominantly female cohort with multiple metabolic comorbidities—reflective of U.S. clinical obesity practice.
| Endpoint | Orforglipron 36 mg | Placebo | p-value |
|---|---|---|---|
| Waist circumference | −9.8 cm | −2.1 cm | < 0.001 |
| Systolic BP | −6.2 mmHg | −1.4 mmHg | < 0.01 |
| Fasting glucose | −7.8 mg/dL | −1.2 mg/dL | < 0.001 |
| HbA1c (prediabetes) | −0.4% | −0.1% | < 0.01 |
| Triglycerides | −18% | −4% | < 0.01 |
| Non-HDL cholesterol | −8.5% | Placebo | < 0.01 |
| C-reactive protein | −47.7% | Placebo | < 0.001 |
Results indicate broad metabolic benefit consistent with GLP-1 physiology.
ATTAIN-1 demonstrates that orforglipron achieves clinically meaningful weight loss (~11%) in adults with obesity—substantially better than oral semaglutide (6-8%) and approaching the lower range of injectable GLP-1 efficacy. The no-fasting requirement and once-daily dosing may improve adherence compared to oral semaglutide. However, efficacy remains lower than tirzepatide (20.9%) or semaglutide 2.4mg (14.9%), positioning orforglipron as a middle-ground option for patients who cannot or prefer not to use injections.
Type 2 Diabetes Trial
- A1C: −2.2% (orforglipron) vs −1.4% (Rybelsus), difference −0.8% (p < 0.001)
- Weight: −9.2% vs −5.3%, difference −3.9% (p < 0.001)
- 37% achieved A1C < 5.7% (near-normal) vs 13% on Rybelsus
- Superior adherence: 92% vs 84% (p = 0.02)
First oral GLP-1 to demonstrate both non-inferiority and superiority over Rybelsus in type 2 diabetes. The no-fasting requirement likely contributed to better adherence (92% vs 84%), addressing a key barrier with oral semaglutide.
These data strengthen orforglipron's competitive positioning in the oral diabetes market. Combined with ATTAIN-1 obesity data, supports FDA submission in late 2025 for dual indications (diabetes + obesity).
- Type 2 diabetes for ≥3 months
- A1C 7.0–10.5% on current therapy
- Taking metformin with or without sulfonylurea
- BMI ≥ 25 kg/m²
- Ages 18-75 years
- Type 1 diabetes or secondary diabetes
- Recent GLP-1 receptor agonist use
- Severe renal impairment (eGFR < 30)
ACHIEVE-3 compared orforglipron 45 mg daily to oral semaglutide 14 mg daily (highest approved dose of Rybelsus).[3]
Dose Selection Rationale
- Orforglipron 45 mg: Optimized dose for type 2 diabetes (higher than 36 mg obesity dose to maximize glycemic control)
- Oral Semaglutide 14 mg: Maximum approved dose of Rybelsus, representing best-case comparator
Dosing Convenience: Unlike oral semaglutide which requires 30-minute fasting before and after dosing, orforglipron can be taken with or without food—eliminating a major adherence barrier.
- A1C < 5.7% (near-normal): 37% (orforglipron 36mg) vs 13% (Rybelsus 14mg) — nearly 3x as many participants achieved near-normal blood sugar (p < 0.001)
- A1C < 7% target: Data shows consistent superiority across all glycemic thresholds, with orforglipron helping significantly more participants reach guideline-recommended targets
- ≥5% weight loss: Higher proportion achieved with orforglipron across all doses compared to comparable semaglutide doses
- Clinical Implication: The substantial advantage in achieving near-normal A1C levels (< 5.7%) represents a meaningful clinical benefit, potentially reducing need for treatment intensification and lowering long-term complication risk.[4]
Treatment effects were evaluated across key patient subgroups to assess the consistency of orforglipron's superior efficacy:[4]
- By Baseline A1C: Orforglipron demonstrated superiority over oral semaglutide regardless of baseline glycemic control. Patients with A1C ≥8.5% showed particularly robust responses, though significant benefits were also seen in those with A1C <8.5%.
- By Baseline BMI: Weight loss superiority was maintained across BMI categories (BMI <30 kg/m² and ≥30 kg/m²), indicating efficacy for both overweight and obese patients with type 2 diabetes.
- By Background Therapy: Orforglipron's advantages were consistent whether patients were taking metformin alone or metformin plus other oral glucose-lowering medications, suggesting compatibility with common diabetes regimens.
- By Diabetes Duration: Benefits were observed across diabetes duration subgroups, indicating efficacy in both recently diagnosed and longstanding type 2 diabetes.
Clinical Implication: The consistent superiority across subgroups reinforces orforglipron's position as a broadly effective oral GLP-1 option for diverse patients with type 2 diabetes.
| Characteristic | Orforglipron 45 mg | Rybelsus 14 mg |
|---|---|---|
| Mean Age | ~58 yrs | ~57 yrs |
| Female | 48% | 50% |
| Mean BMI | 32.8 kg/m² | 32.5 kg/m² |
| Mean Baseline A1C | 8.4% | 8.5% |
| Mean T2D Duration | 8.2 years | 8.0 years |
| On Metformin Only | 62% | 64% |
| On Metformin + Other | 38% | 36% |
Typical primary-care diabetes population on oral therapy with moderate glycemic dyscontrol.
| Endpoint | Orforglipron 45 mg | Rybelsus 14 mg | p-value |
|---|---|---|---|
| A1C < 5.7% (near-normal) | 37% | 13% | < 0.001 |
| Fasting glucose | −48 mg/dL | −38 mg/dL | < 0.01 |
| Systolic BP | −5.8 mmHg | −4.2 mmHg | 0.15 |
| Triglycerides | −22% | −18% | 0.22 |
| Adherence (≥80%) | 92% | 84% | 0.02 |
Nearly 3x as many participants achieved near-normal blood sugar (A1C < 5.7%) with orforglipron. Improved adherence likely reflects the absence of fasting restrictions.
ACHIEVE-3 establishes orforglipron as the first oral GLP-1 to demonstrate superiority over oral semaglutide (Rybelsus) in both glycemic control and weight loss. The 0.8% incremental A1C reduction is clinically meaningful in diabetes management, and the superior adherence (92% vs 84%) likely reflects the elimination of fasting requirements—a key barrier with Rybelsus. This positions orforglipron as a compelling option for patients seeking oral therapy without injection or fasting restrictions, though efficacy remains below injectable GLP-1s like tirzepatide.
Safety
Adverse Events
| Adverse Event | Incidence (%) | Comparator | Note |
|---|---|---|---|
| Nausea | 38–42 | Placebo 12 / Rybelsus 32 | Mostly mild to moderate |
| Diarrhea | 25–28 | 10–22 | Transient |
| Vomiting | 18–22 | 6–15 | During titration |
| Constipation | 15–18 | 8–14 | Self-limited |
| Headache / Dizziness | ~10 | < 10 | Non-serious |
Serious Adverse Events: Low (< 5%) and balanced between groups.[1,5] No pancreatitis or thyroid carcinoma reported. Severe hypoglycemia was rare (< 1%). No cardiovascular signal detected, though CV outcomes trials are ongoing.
Access
Trial Status
- ATTAIN-1 and ACHIEVE-3 completed (September 2025)
- Extension and outcomes studies under review
- FDA approved as Foundayo on April 1, 2026
Participation Opportunities
To check active studies:
- Visit ClinicalTrials.gov
- Search "orforglipron" or "LY3502970"
- Filter for "Recruiting" or "Not yet recruiting"
- Discuss eligibility with a qualified healthcare provider
FAQs
ATTAIN-1 showed ~11% weight loss at 72 weeks; ACHIEVE-3 showed −2.2% A1C and −9.2% weight change — both superior to comparators.
Yes. The FDA approved orforglipron as Foundayo for chronic weight management on April 1, 2026.
Efficacy is slightly below Wegovy (~15%) and Zepbound (~20%) but above Rybelsus (6–8%), with simpler oral dosing.
Gastrointestinal effects such as nausea and vomiting, mainly during dose increase; serious adverse events are uncommon.
Main Phase 3 studies are complete; check extension or outcomes trials for open enrollment on ClinicalTrials.gov.
In the head-to-head ACHIEVE-3 trial, orforglipron demonstrated superior efficacy compared to oral semaglutide (Rybelsus). For patients with type 2 diabetes, orforglipron achieved greater A1C reduction (−2.2% vs −1.4%) and greater weight loss (−9.2% vs −5.3%). Additionally, orforglipron offers a dosing advantage: it can be taken with or without food at any time of day, whereas Rybelsus requires fasting for 30 minutes before eating. This flexibility may improve adherence and convenience for patients.
The clinical trials evaluated multiple doses of orforglipron. In ATTAIN-1, participants received either 24 mg, 36 mg, or 45 mg daily doses. The 45 mg dose produced the greatest weight loss (11.2% at 72 weeks) and is expected to be the approved dose if the FDA grants approval. In ACHIEVE-3, the comparison trial against oral semaglutide, orforglipron was also escalated to 45 mg daily. All participants started at a lower dose (3 mg) and gradually increased over 16 weeks to minimize gastrointestinal side effects—a standard approach for GLP-1 medications.
Yes, all primary endpoints in both ATTAIN-1 and ACHIEVE-3 achieved high statistical significance (p < 0.001). This means there is less than a 0.1% probability that the results occurred by chance alone. In statistical terms, these findings are extremely robust. For ATTAIN-1, the 11.2% weight loss with orforglipron versus 2.0% with placebo was highly significant. In ACHIEVE-3, both the A1C reduction and weight loss superiority over oral semaglutide were statistically significant. These strong statistical results, combined with the large sample sizes and rigorous trial designs, provide high confidence in orforglipron's efficacy.
Citations
- Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796-1806. https://pubmed.ncbi.nlm.nih.gov/40960239/
- ClinicalTrials.gov. A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1). NCT05869903. https://clinicaltrials.gov/study/NCT05869903
- ClinicalTrials.gov. A Study of Orforglipron in Adults With Type 2 Diabetes (ACHIEVE-3). NCT06045221. https://clinicaltrials.gov/study/NCT06045221
- Eli Lilly and Company. Lilly's Oral GLP-1 Orforglipron Superior to Oral Semaglutide in Head-to-Head Type 2 Diabetes Trial. Press Release, September 17, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head
- Clinical Trials Arena. Lilly's Orforglipron Trumps Oral Semaglutide in Head-to-Head Trial. September 17, 2025. https://www.clinicaltrialsarena.com/news/lillys-orforglipron-trumps-oral-semaglutide-in-head-to-head-trial/
- Eli Lilly and Company. Lilly's Oral GLP-1 Orforglipron Demonstrated Meaningful Weight Loss and Cardiometabolic Improvements in ATTAIN-1. Press Release, September 16, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-meaningful-weight
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Bucheit JD, Pamulapati LG, Carter N, Malloy K, Dixon DL, Sisson EM. Oral Semaglutide: A Review of the First Oral GLP-1 Receptor Agonist. Diabetes Technol Ther. 2020;22(1):10-18. https://pubmed.ncbi.nlm.nih.gov/31436480/
Last updated October 6, 2026 · Key facts verified October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.